Compare Toronto-Dominion Bank (TD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

TD (Toronto-Dominion Bank) trades at $117.63, up 0.98% today, with a bearish technical signal but strong fundamentals including a P/E of 18.01 and net income margin of 24.88%. Recent earnings have consistently beaten estimates, and the company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30). Cash flow trends show volatility, with 2025 net cash flow at $1.08 billion. The stock faces headwinds from a high debt-to-asset ratio of 20.86 in 2025, though analyst consensus is bullish with 52.94% buy ratings.

The outlook for TD is mixed: solid profitability and shareholder returns via buybacks and dividends support upside, but technical weakness and elevated debt pose risks. Investors should weigh strong earnings momentum against macroeconomic sensitivity and regulatory scrutiny from ongoing anti-money laundering remediation. The stock's valuation appears reasonable relative to peers, but market sentiment remains cautious due to cash flow inconsistencies.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.